|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:activities
|
IL-12 and IL-23 inhibitor
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:category
|
gptkb:unknown
B
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
gptkb:unknown
Phase 3
moderate to severe plaque psoriasis
moderate to severe ulcerative colitis
moderate to severe Crohn's disease
IM-UNITI
PSUMMIT-1
PSUMMIT-2
UNITI-1
UNITI-2
|
|
gptkbp:contraindication
|
active infections
history of hypersensitivity to ustekinumab
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:effective_date
|
September 2009
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:formulation
|
auto-injector
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Stelara
|
|
gptkbp:ingredients
|
gptkb:ustekinumab
|
|
gptkbp:interacts_with
|
immunosuppressants
live vaccines
TNF inhibitors
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_monitored_by
|
infections
tuberculosis
malignancies
|
|
gptkbp:is_used_for
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
psoriasis
|
|
gptkbp:lifespan
|
15 days
|
|
gptkbp:manager
|
subcutaneous
subcutaneous injection
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Asia
gptkb:Australia
gptkb:Latin_America
gptkb:North_America
Stelara (ustekinumab)
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:rounds
|
primarily renal
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
thrombosis
injection site reactions
serious infections
hypersensitivity reactions
malignancies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:T_cells
dendritic cells
|